ClinicalTrials.gg
CompletedNCT02183025Updated Aug 31, 2018

Efficacy and Safety Study of Meloxicam Versus Mefenamic Acid in Patients With Dysmenorrhea

A Phase 2 interventional study of Meloxicam 7.5 mg and Meloxicam 15 mg in Dysmenorrhea, sponsored by Boehringer Ingelheim. Completed. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2018-08-31.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
337
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

To access the efficacy and safety of Meloxicam 7.5 mg and 15 mg once daily compared with Mefenamic acid 500 mg t.i.d. over a treatment period of 3-5 days, during an observation period of 3 menstrual cycles, for the symptomatic relief of primary dysmenorrhea

02

Conditions studied

  • Dysmenorrhea

Browse trials for

03

In context

Dysmenorrhea

432 studies on the registry are indexed under Dysmenorrhea; 109 are open to participants now.

This study's enrollment of 337 is above the median of 62 across 364 interventional studies indexed under Dysmenorrhea.

Browse Dysmenorrhea studies →

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients between 18 to 40 years
  • Patients experiencing primary (functional) dysmenorrhea during the last 3 consecutive menstrual periods. Diagnosis will be based on symptoms and clinical signs: abdominopelvic pain, may radiate to the back and along the thighs; systemic symptoms including nausea, vomit, diarrhoea, headache, fatigue, nervousness, dizziness; the symptomatology should be usually some hours to one day before commencement of visible vaginal bleeding
  • Evaluation of lumbar and/or abdominopelvic pain due to dysmenorrhea > 35 mm through a 100 mm visual analogue scale (VAS)
  • Outpatients
  • Patients granting their written
  • Therapy with a NSAID (nonsteroidal antiinflammatory drug) is required or recommended

Exclusion criteria

Exclusion Criteria:

  • Known or suspected to trial drugs or their , analgesics, antipyretics or NASIDs
  • Analgesic concomitant treatment (between each cycle paracetamol administration will be allowed)
  • To initiate hormonal or intrauterine devices after inclusion to this trial or during the last 3 months
  • Abdominal surgery or pelvic procedure scheduled during the study
  • Patients with organic dysmenorrhea (endometriosis, salpingitis, adnexitis, uterine retroversion, tubal cysts, ovarian cysts, pathological vaginal secretion, painful pelvic exploration, etc.)
  • Patients with neoplastic disorders
  • History of recent abdominal or pelvic trauma requiring surgery
  • Peptic ulcer within the past 6 months
  • Pregnancy or breast feeding
  • Asthma, nasal polyps, angioneurotic edema or rash following aspirin or NSAIDs administration
  • Concomitant treatment with anti-coagulants, including heparin and aspirin, lithium or methotrexate
  • Concomitant administration of other NSAIDs (including aspirin > 150 mg daily) or analgesics
  • Confinement to bed rest
  • Administration of any NSAID during two days (three for oxicams) before the first administration of the trial drug
  • Present treatment or treatment within the last two months with
  • Impaired renal function (serum urea > 125 % of the ; serum creatinine > 150 % of the upper limit of normal range)
  • Sever liver injury (alanine amino transferase ALAT > 2 x the upper normal range limit or aspartate amino transferase ASAT > 2 x the upper normal range limit)
  • Hematological disorder ( count \< 100,000/mm**3, leucocyte count \< 3,000/mm**3)
  • Participation in another clinical trial during this study or the previous month
  • Previous participation in this trial
  • Patient unable to comply with protocol
  • Bleeding disorders
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
337 participants (actual)

Study arms

  • Experimental
    Meloxicam 7.5 mg

    Drug: Meloxicam 7.5 mg · Drug: Placebo matching 15 mg meloxicam · Drug: Placebo matching 500 mg mefenamic acid

  • Experimental
    Meloxicam 15 mg

    Drug: Meloxicam 15 mg · Drug: Placebo matching 7.5 mg meloxicam · Drug: Placebo matching 500 mg mefenamic acid

  • Active comparator
    Mefenamic acid 1500 mg

    500 mg three times daily

    Drug: Mefenamic acid 500 mg · Drug: Placebo matching 7.5 mg meloxicam · Drug: Placebo matching 15 mg meloxicam

Interventions

06

What researchers measure

Primary outcomes

  1. Evaluation of severity of lumbar and/or abdominal pain on a visual analogue scale (VAS)

    Time frame: Baseline and day 3-5 of each treatment cycle

Secondary outcomes

  1. Final global assessment of efficacy by patient on a 4-point scale

    Time frame: day 3-5 of the second treatment cycle

  2. Final global assessment of efficacy by investigator on a 4-point scale

    Time frame: day 3-5 of the second treatment cycle

  3. Final global assessment of tolerability by patient on a 4-point scale

    Time frame: day 3-5 of the second treatment cycle

  4. Final global assessment of tolerability by investigator on a 4-point scale

    Time frame: day 3-5 of the second treatment cycle

  5. Number of Participants with Adverse Events (AE)

    Time frame: Up to 4 weeks after last treatment cycle

  6. Incidence of significant laboratory events

    Time frame: Up to 4 weeks after last treatment cycle

  7. Number of perforations, ulcerations and/or bleedings (PUB) of the upper gastro-intestinal tract

    Time frame: Up to 4 weeks after last treatment cycle

  8. Number of gastro-intestinal adverse events (GI-AEs)

    Time frame: Up to 4 weeks after last treatment cycle

  9. Duration of hospitalization stay due to GI-AEs

    Time frame: Up to 4 weeks after last treatment cycle

  10. Number of additional visits at physician due to GI-AEs

    Time frame: Up to 4 weeks after last treatment cycle

  11. Duration of hospitalization due to drug related AEs

    Time frame: Up to 4 weeks after last treatment cycle

  12. Number of withdrawals due to AEs

    Time frame: Up to 4 weeks after last treatment cycle

  13. Intensity of AEs on a 3-point scale

    Time frame: Up to 4 weeks after last treatment cycle

  14. Evaluation of labor and/or daily life disability associated with dysmenorrhea on a VAS

    Time frame: Baseline and day 3-5 of each treatment cycle

  15. Change in severity of symptomatology associated with dysmenorrhea

    Time frame: Baseline and day 3-5 of each treatment cycle

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 1998 and a primary completion of Apr 1999. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2014
First posted
Jul 8, 2014
Start
Jan 1998
Primary completionActual
Apr 1999
Last update
Aug 31, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02183025
Responsible party
Sponsor
First posted
Jul 8, 2014
Start date
Jan 1998
Primary completion
Apr 1999
Last update
Aug 31, 2018
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Meloxicam

Start the discussion